Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

Wall Street analysts forecast that Pfizer (PFE) will report quarterly earnings of $0.66 per share in its upcoming release, pointing to a year-over-year decline of 37.7%. It is anticipated that ...